It is very uncertain whether taxane‐platinum‐fluoropyrimidine combinations changes overall survival compared with taxane‐platinum (without fluoropyrimidine) (very low certainty).
Taxane‐platinum‐fluoropyrimidine combinations may leads to higher tumour response compared with taxane‐platinum (without fluoropyrimidine) (low certainty).
Taxane‐platinum‐fluoropyrimidine combinations probably leads to lower progression‐free survival compared with taxane‐platinum (without fluoropyrimidine) (moderate certainty).
It is very uncertain whether taxane‐platinum‐fluoropyrimidine combinations changes treatment‐related death compared with taxane‐platinum (without fluoropyrimidine) (very low certainty).
It is very uncertain whether taxane‐platinum‐fluoropyrimidine combinations changes treatment discontinuation due to toxicity compared with taxane‐platinum (without fluoropyrimidine) (very low certainty).
Gemcitabine combinations showed no clear difference in overall survival ‐ Gemcitabine plus platinum agent compared with gemcitabine alone (low certainty).
The intervention showed no clear difference in chemobased OS ‐ Platinum‐based chemotherapy OS (moderate certainty).
The intervention showed no clear difference in chemobased DFS ‐ Platinum‐based chemotherapy DFS (moderate certainty).